Volver

Pfizer Inc

Ticker: PFE ISIN: US7170811035
Añadir al portafolio Análisis de cartera en 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Capitalización
152,39 MM $
P/E
19,70
Forward P/E
9,14
Profit margin
12,42%
Revenue growth QoQ
-1,20%
Div. yield
6,37%
Beta
0,39
27,66 $ 0,07%
Precio a fecha de 2026-09-18 · NYSE

Rendimiento por período

Rendimientos acumulados
1 Month -1,11%
6 Months +6,87%
1 Year +23,13%
5 Years -3,89% p.a.-18,00%
10 Years +2,97% p.a.+34,04%
Since inception +2,75% p.a.+96,95%
Rendimientos por año
YTD +16,82%
2025 +0,65%
2024 -2,22%
2023 -41,26%
2022 -10,41%
2021 +66,69%

Key stats

Market cap
152,39 MM
P/E
19,70
Dividend yield
6,37%
Beta
0,39
52-week range
20.87 - 28.75
50-day MA
27,20
200-day MA
25,66
Section 1

Business overview

Company profile data from fundamentals.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 8,89%
ROA 5,68%
Profit margin 12,42%
Operating margin 23,95%
PEG ratio 13,77
Revenue/share TTM 11,01
Revenue TTM 62,58 MM
EBITDA 25,72 MM
Gross profit TTM 47,44 MM
Beta 0,39

Valuation

Trailing P/E 19,70
Forward P/E 9,14
P/B 1,76
P/S 2,44
EV/EBITDA 12,08
EV/Revenue 3,24
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 2,96
Quarterly earnings growth -21,30%
Revenue TTM 62,58 MM
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 6,37%
Dividend per share 1,7200
Next dividend date 2026-06-12
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Short ratio 3,45
Short % of float 2,35%

Details

Instrument metadata and source update timestamps.

Symbol PFE
Name Pfizer Inc
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US7170811035
Country USA
Code + exchange PFE.NYSE
Last price date 2026-04-28
Fundamentals updated 2026-04-29

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.